CureVac initiates phase I trial of RNAdjuvant for solid tumors

Tuesday, October 31, 2017

CureVac, a fully-integrated biotechnology company pioneering mRNA-based drugs, has initiated a phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

[Read More]

CureVac appoints Daniel Menichella as CEO of U.S. Subsidiary

Wednesday, May 3, 2017

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, has announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston-based U.S. subsidiary. Menichella, an experienced executive in the biotech industry, will develop CureVac’s U.S. organization with a clear focus on business and corporate development activities around CureVac’s versatile mRNA technology platform.

[Read More]